NVO
New deal, bigger map
Anthropic and OpenEvidence are expanding a free AI-powered clinical decision-support tool to almost 100 low- and middle-income countries. Think of it like giving doctors a supercharged medical search engine that actually knows the local lay of the land — from disease patterns to what resources are available.
Why this matters
The tool is already free for clinicians in the U.S. and Europe, but this rollout stretches it into places like Uganda, Angola, Sudan, Haiti, and Mongolia. OpenEvidence says the platform answers physicians’ questions using peer-reviewed research and treatment guidelines, while Anthropic is handling the back-end AI muscle.
- OpenEvidence says the system is meant to be "context adaptive," which is a fancy way of saying the software won’t pretend a smartphone and spotty electricity are the same as a polished hospital system.
- The companies say the goal is to make medical knowledge less dependent on geography.
- Anthropic’s logo here is doing more than moral support: it’s helping prove its AI can be useful in regulated, high-stakes environments.
The investor angle
This isn’t Novo Nordisk news, even though NVO gets a shoutout because Anthropic separately partnered with Novo on AI drug research. The real story is that Anthropic is widening its healthcare footprint, and that’s the kind of use-case expansion investors love to see when they’re trying to figure out if AI is more than a flashy demo.
Big picture: this is less "chatbot hype" and more "AI quietly moving into the doctor’s toolkit," which is where the long-term story gets interesting.